BNP PARIBAS ASSET MANAGEMENT Holding S.A. Increases Stock Holdings in AbbVie Inc. $ABBV

BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in AbbVie Inc. (NYSE:ABBV) by 44.1% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 487,025 shares of the company’s stock after buying an additional 148,970 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in AbbVie were worth $111,854,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Ellenbecker Investment Group raised its position in shares of AbbVie by 0.8% during the 3rd quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock worth $1,235,000 after purchasing an additional 44 shares during the last quarter. Security National Bank of Sioux City Iowa IA increased its position in AbbVie by 0.3% during the third quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock worth $3,562,000 after buying an additional 45 shares in the last quarter. Matthew Goff Investment Advisor LLC raised its holdings in shares of AbbVie by 0.3% in the third quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock worth $4,066,000 after acquiring an additional 45 shares during the last quarter. Centennial Wealth Advisory LLC lifted its position in shares of AbbVie by 2.2% in the third quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock valued at $484,000 after acquiring an additional 45 shares in the last quarter. Finally, Willner & Heller LLC boosted its stake in shares of AbbVie by 0.6% during the third quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock valued at $1,759,000 after acquiring an additional 46 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ABBV has been the subject of several analyst reports. UBS Group cut their target price on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a research note on Thursday, February 5th. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and lifted their price target for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Evercore reduced their price objective on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 4th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and issued a $223.00 price target on shares of AbbVie in a report on Wednesday, January 28th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $252.79.

AbbVie Stock Down 2.0%

ABBV stock opened at $224.13 on Friday. The company has a market cap of $396.12 billion, a price-to-earnings ratio of 94.97, a PEG ratio of 0.80 and a beta of 0.35. The business has a fifty day simple moving average of $224.01 and a 200-day simple moving average of $221.70. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The firm’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.1%. The ex-dividend date is Wednesday, April 15th. AbbVie’s payout ratio is currently 293.22%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Board declared a quarterly cash dividend of $1.73 per share (annualized yield ~3.1%), payable May 15 to holders of record April 15 — supports income investor demand and underscores management’s commitment to returning cash. AbbVie Declares Quarterly Dividend
• Positive Sentiment: Investment write-ups highlight AbbVie as a Dividend King and a multi-area biotech with durable cash flows — narrative that attracts dividend-focused buyers. 2 Dividend Stocks to Hold for the Next 5 Years
• Positive Sentiment: VOLITE skin-quality trial reported completion updates — clinical progress in aesthetics could help diversify revenue beyond core immunology franchises. AbbVie’s VOLITE Skin Quality Trial Completion
• Positive Sentiment: Coverage pieces suggest AbbVie’s post-Humira pipeline progress (Tremfya and others) could prompt renewed investor interest if share gains and new launches continue. This is a potential catalyst for medium-term revenue growth. Should AbbVie’s Post-Humira Pipeline Progress Prompt a Fresh Look From Investors?
• Neutral Sentiment: AbbVie launched a branded podcast, “The Persistence Lab,” to highlight innovation — helpful for PR/brand but unlikely to move fundamentals quickly. AbbVie heads to ‘The Persistence Lab’
• Neutral Sentiment: Analyst commentary and aggregator pieces (Zacks, Yahoo Top Analyst Reports) continue to highlight AbbVie following its earnings beat — supportive background but mixed across firms. The Zacks Analyst Blog
• Negative Sentiment: Evercore trimmed its price target slightly and warned that while Tremfya is gaining share, future earnings growth could be limited — a caution that may restrain upgrades and cap near-term upside. Evercore Notes Tremfya Gains Market Share

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.